The age of the target cell affects B-cell leukaemia malignancy

Carolina Vicente-Dueñas¹, Fernando Abollo-Jiménez¹, Lucía Ruiz-Roca¹, Esther Alonso-Escudero¹, Rafael Jiménez², María Begoña García Cenador³, Francisco Javier García Criado³, César Cobaleda⁴, and Isidro Sánchez-García¹

¹ Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/ Universidad de Salamanca, Campus M. de Unamuno s/n, 37007- Salamanca, Spain
² Departamento de Fisiología y Farmacología, Universidad de Salamanca, Edificio Departamental, Campus M. de Unamuno s/n, 37007- Salamanca, Spain
³ Departamento de Cirugía, Universidad de Salamanca, Spain
⁴ Centro de Biología Molecular Severo Ochoa, CSIC/Universidad Autónoma, Madrid, Spain

Keywords: B-cell leukaemia, age, target cell, BCR-ABL

Received: 12/03/10; accepted: 12/10/10; published on line: 12/11/10

Corresponding authors: Carolina Vicente-Dueñas, PhD and Sánchez-García, PhD; E-mail: cvd@usal.es; isg@usal.es

Copyright: © Vicente-Dueñas et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract: The incidence, malignancy and treatment resistance of many types of human B-cell leukaemias (B-ALL) are directly related to patient age. A major obstacle to elucidate the contribution of age to the development and evolution of leukaemias is the lack of appropriate mouse models where precise control of the timing of oncogene expression is possible. Here we present proof-of-principle experiments showing how a conditional transgenic mouse model of BCR-ABLp190-driven B-ALL offers the opportunity to test the hypothesis that the age of the leukemic cells-of-origin of B-ALL influences B-ALL malignancy. B-ALLs generated from 12- and 20-month-old progenitors gave rise to a more invasive B-ALL than the one developed from 4-month old precursors. This was evidenced by survival analysis revealing the increased malignancy of B-ALLs generated from 20 or 12-month-old transformed progenitors compared with the 4-month equivalents (median survival of 88 days versus 50.5 and 33 days, respectively). Our study shows that the age of target cells at the time of transformation affects B-ALL malignancy.

INTRODUCTION

An improved understanding of B cell lineage acute lymphoblastic leukaemia (B-ALL) pathophysiology has been gained in the process of identification of the genetic abnormalities consistently present in B-cell blasts [1-3]. A rather limited variety of gene fusions created by chromosomal translocations are involved in the genesis of B-ALL: basically TEL-AML1, MLL rearrangements, BCR-ABL and E2A-PBX1 [2, 4]. However, the frequency of genetically defined leukaemia subtypes differs between children and adults: for example, TEL-AML1 leukaemias are almost exclusively present in children (22% of ALLs vs 2% in the adults) while BCR-ABL ALLs are much more frequent in adults (25% vs. 3% in children) [2, 4, 5]. BCR-ABL¹ (and, in most of the cases, specifically the BCR-ABLp190 protein form) represents the most frequent cytogenetic abnormality (25–30% of cases) in adults and defines the B-ALL subset with the most unfavorable prognosis [6]. Increased age has a negative impact on human B-ALL survival and directly correlates with increased incidence, malignancy, and treatment resistance [3]. However, little is known about age-related mechanisms that impact B-ALL malignancy. There are many evidences indicating that aging has a clear impact both in the numbers and in the functionality of stem cells [7-12] and B lymphoid progenitors [13-15]. It has been described that BCR-ABLp190 leukaemias have to originate from early progenitors/stem cells, given the fact that the oncogene cannot by itself endow the target cell with stem cell properties [16]. The same conclusion is supported by...
transplantation experiments of human B-ALL purified subpopulations into immunocompromised mice [4, 17, 18]. Therefore, any impact that age might have on the target cell-of-origin population may reflect in the characteristics of the leukemic disease.

A major obstacle to elucidate the contribution of age to the development and evolution of leukaemias is the lack of appropriate mouse models where precise control of the timing of oncogene expression is possible. Here we present proof-of-principle experiments showing how a conditional transgenic mouse model of BCR-ABLp190-driven B-ALL offers the opportunity to evaluate the impact of age-related mechanisms in B-ALL malignancy.

RESULTS AND DISCUSSION

Survival of BCR-ABL+ ALL cells is cell-autonomous and independent of the host’s age

To determine the impact of host age on the survival of BCR-ABL+ leukemic cells, 1 x 10^5 cells of a characterized B-ALL cell line Ba/F3-p190 [19] were injected intravenously into syngeneic host mice of 4 (n = 16) or 20 (n = 11) months of age. Injected mice started to die due to leukemic infiltration (data not shown) around 20 days post-injection. Kaplan-Meier survival plot demonstrates that there is no difference in survival between young or old recipient mice (log rank test \( P = 0.9011 \)) (Figure 1). These results indicate that host age does not influence BCR-ABL+ ALLs malignancy.

Figure 1. Host age does not affect survival outcome. To determine the impact of host age on survival, 1 x 10^5 cells of a characterized B-ALL cell line Ba/F3-p190 (REF) were IV injected into syngeneic host mice aged 4 months (n = 16) or 20 months (n = 11). Kaplan-Meier survival plot demonstrates no difference in survival (log rank test \( P = 0.9011 \)).

Figure 2. Transformed hematopoietic progenitor/stem cells express comparable levels of exogenous \textit{BCR-ABL}. Expression of \textit{BCR-ABL} was measure by real-time PCR in BM cells of CombitTA-p190 mice at the age of 4 months, 12 months, and 20 months. Doxycycline was given at 4mg/mL for 4 months, 12 months, and 20 months. \textit{BCR-ABL expression} was measured in CombitTA-p190 mice under doxycycline treatment (+) and mice of the same age once the doxycycline has been removed (-). The mean Ct values of triplicate assays are presented. (BM, bone marrow; wt, wild-type).
Age-dependent malignancy of transformed hematopoietic progenitor cells in vivo

As mentioned, BCR-ABLp190+ ALLs have been identified as being originated in cells with the characteristics of a stem cell, and there are many evidences indicating that aging affects both the numbers and the functionality of stem cells and B lymphoid progenitors. Therefore, to investigate if the age of the target cells also has an impact in malignant development, we have taken advantage of the doxycycline-controlled transgenic CombitTA-BCR-ABLp190 mouse line [20] to induce the expression of the leukaemia-triggering oncogene in mice of different ages. The CombitTA-BCR-ABL-p190 mice expressing the BCR-ABLp190 chimeric gene product have previously been described to consistently show the B-ALL pathologic phenotype with which this oncogene is associated in humans [20]. In the present work, BCR-ABLp190 expression was activated in CombitTA-BCR-ABL-p190 mice of different ages.

Figure 3. Age-dependent malignancy of transformed hematopoietic progenitor cells in vivo. (A) Kaplan-Meier survival analysis. Animals where BCR-ABL expression was induced at 4-month of age survived significantly longer than animals where BCR-ABL expression was induced at 12- or 20-month of age (median survival of 88 days versus 50.5 and 33 days, respectively; log rank $P < 0.0001$ and $0.0001$, respectively). (B) CombitTA-p190 mice were evaluated for disease progression by flow cytometry. Cells from peripheral blood of CombitTA-p190 and control mice were analyzed by flow cytometry with combination of the specific myeloid (Mac1) and B-cell lymphoid (B220) markers. A representative flow cytometry analysis is shown Characteristic blast cells in BCR-ABL B-cell leukaemia co-expressed B-cell and myeloid markers indicated by the presence of Mac'B220' cells. (C) Variability on the percentage of blast cells in the peripheral blood as a function of donor age.
different ages (4-, 12- and 20-month, respectively) by removing the doxycycline from the drinking water. All mice demonstrated equivalent levels of exogenous BCR-ABL expression, thus precluding any effect from transgene expression changes with age (Figure 2).

In order to test the age-dependent malignancy of transformed hematopoietic progenitor cells in vivo in the least biased manner possible, and to exclude any potential non cell-autonomous, age-related, effect on the disease evolution, bone marrow cells were purified from CombitTA-BCR-ABLp190 sacrificed mice in which BCR-ABL expression had been kept repressed all life. Then, cells from donors sacrificed at either 4-, 12- or 20-months were injected intravenously into syngenic host mice of 4 months of age. This transplantation into a non doxycyclin-treated recipient lead to transgene derepression and expression of the oncogene in a simultaneous manner. 100% of the injected mice developed B-ALL with all the phenotypic characteristics previously described for the CombitTA-BCR-ABLp190 mice [20], namely the presence in the peripheral blood of organ-infiltrating blast cells co-expressing B-cell and myeloid markers (Figure 3). However, B-ALL derived from 12- and 20-month transformed HSCs could be distinguished by two distinct but interrelated relevant features: first, 20-month-ALLs presented increased cellularity of B220, Mac1 co-expressing blasts (Figure 3B-C). Second, and most importantly, animals with B-ALL derived from 4-month-old donors survived nearly twice as long as those with B-ALL from 12- and 20-month-old donors (88 versus 50.5 and 33 days, respectively; log rank \( P < 0.0001 \) and 0.0001, respectively; Figure 3A). These findings therefore prove that the malignancy of B-ALL increases with the age of the leukemic-cell-of-origin (i.e., with the age of the normal progenitors from which the disease arises). Leukaemias originating from older progenitors present a more aggressive phenotype, and have a much faster evolution, than leukaemias initiating in young progenitors. Our results also show that, to a great extent, disease evolution is programmed from the beginning, since the starting cell determines the aggressiveness of the phenotype, and also that the decline of the immune response with age is not responsible for the increased development or aggressiveness of the tumours in the elderly. In agreement with these observations it has been recently shown, using a retroviral transduction system, that aged B-cell progenitors present a reduced fitness due to impaired signaling machinery and that this, since the oncogene covers in part the need for kinase signaling, promotes the positive selection for BCR-ABL* cells [21].

In summary, our study of B-ALL provides the first in vivo experimental evidence, using a conditional transgenic mouse model, showing that an increase in the age at which transformation occurs has a direct impact in the malignant potential of cancer cells. This is in agreement with clinical observations showing that age-related cell intrinsic factors may play a leading role in the impact of age on B-ALL malignancy [3]. Also, these findings further support the clinical relevance of this model and its usefulness for future studies to determine how specific oncogenic mechanisms affect age-related malignancy, and to determine how age-related cell-extrinsic host mechanisms such as immune function and others impact B-ALL malignancy.

**METHODS**

**Cell culture.** Cell lines used include Ba/F3 cells expressing the human protein BCR–ABL\(^{190} \) (Ba/F3-p190) [19]. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS).

**Mice and transplantation experiments.** The CombitTA-BCR-ABL\(^{190} \) mice have been previously described [20]. In order to investigate the impact of age of the target cells in B-ALL malignancy, bone marrow transplantation experiments were performed. BM cells were isolated and highly purified from either 4-, 12- and 20-month old CombitTA-p190 mice that had been kept on doxycycline water for all their life. Marrow cells were flushed from the femurs with a syringe containing 2 mL PBS-1% FBS. In each cohort these BM cells were injected into the tail vein of the irradiated recipient syngenic mouse (4 Gy) at 1 x 10\(^6 \) cells per mouse. All recipients were maintained in microisolator cages on sterilized food and acidified sterile water. Diseased recipient mice were sacrificed and assessed for B-cell leukaemia development. All experiments were done according to the relevant regulatory standards.

**Flow cytometry.** Nucleated cells were obtained from total mouse bone marrow (flushing from the long bones), peripheral blood, thymus, liver or spleen. In order to prepare cells for flow cytometry, contaminating red blood cells were lysed with RCLB lysis buffer and the remaining cells were then washed in PBS with 2% FCS. After staining, all cells were washed once in PBS with 2% FCS containing 2 mg/mL propidium iodide (PI) to allow dead cells to be excluded from both analyses and sorting procedures. Monoclonal antibodies were obtained from Pharmingen. The samples and the data were analyzed in a FACSCalibur using the CellQuest software (Becton Dickinson). Specific fluorescence of FITC and PE excited at 488 nm (0.4 W)
Kaplan-Meier survival plots was performed using the TTATAATCACAATG-3', Tcacaccatt-3', and probe 5'-CCGGGTCTTGGGAAGGTGAA-3', antisense primer 5'-CGTTTGGGCT-3'; c-Abl, sense primer 5'-CACTCTCAGCATCACTAGA-3' and probe 5'-TGGCCCAACGATGGCGAGGG-3', antisense primer 5'-CAGATGCTACTGGCCGCT-3; and 633 nm (30 mW), respectively, as well as known forward and orthogonal light scattering properties of mouse cells were used to establish gates. Unspecific antibody binding was suppressed by preincubation of cells with CD16/CD32 Fc-block solution (BD Pharmingen). For each analysis, a total of at least 5,000 viable (PI-) cells were assessed.

Real-time PCR quantification. To analyze expression of CombiTA-p190 in Sca1 Lin- cells, total RNA was prepared using the Trizol Reagent (Gibco-BRL). Reverse transcription (with random hexamer primers) was performed as described [22]. Real-time quantitative PCR was carried out for the quantitation of CombiTA-p190. Fluorogenic PCRs were set up in a reaction volume of 50 ml using the TaqMan PCR Core Reagent. Fluorogenic PCRs were set up in a reaction volume of 50 ml using the TaqMan PCR Core Reagent kit (PE Biosystems). cDNA amplifications were carried out using the same primers in a 96-well reaction plate format in a PE Applied Biosystems 5700 Sequence Detector. Thermal cycling was initiated with a first denaturation step of 10 min at 95°C. The subsequent thermal profile was 40 cycles of 95°C for 15 s, 56°C for 30 s, 72°C for 1 min. Multiple negative water blanks were tested and a calibration curve determined in parallel with each analysis. The abl endogenous control (PE Biosystem) was included to relate CombiTA-p190 to total cDNA in each sample. The sequences of the specific primers and probe were as follow: BCR-ABLp190-1, sense primer 5'-CCGCAAGAACCGGCGAGAT-3', antisense primer 5'-CAGATGCTACTGGCCGCT-3'; and probe 5'-TGCGCCCAACGATGGCGAGGG-3'; c-Abl, sense primer 5'-CACTCTCAGCATCAGCTA AAGGTGAA-3', antisense primer 5'-CGTTTGGGCT TCACACACTTTTCCAGTTAATCAAGATC-3'.

Statistical analysis. Statistical analysis of differences in Kaplan-Meier survival plots was performed using the Log-rank (Mantel-Cox) test.

ACKNOWLEDGEMENTS

Research in ISG group was partially supported by FEDER and by MICINN (SAF2009-08803 to ISG), by Junta de Castilla y Leon (Proyecto Biomedicina 2009-2010 to ISG), by MEC OncoBIO Consolider-Ingenio 2010 (Ref. CSD2007-0017), by NIH grant (R01 CA109335-04A1), by Sandra Ibarra Foundation, and by Group of Excellence Grant (GR15) from Junta de Castilla y Leon. CVD research is supported by Junta de Castilla y Leon (proyecto de investigación en biomedicina SAN/39/2010). ISG is an API lab of the EuroSyStem project. Research at C.C.’s lab was partially supported by FEDER, Fondo de Investigaciones Sanitarias (PI080164), CSIC P.I.E., Junta de Castilla y Leon (SA060A09 and proyecto Biomedicina 2009-2010) and from an institutional grant from the Fundación Ramón Areces. F.A.-J. was supported by an FPU fellowship from the Spanish Ministerio de Ciencia e Innovacion.

CONFLICT OF INTERESTS STATEMENT

The authors of this paper declare no conflict of interests.

REFERENCES

1. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukaemia in adults. Blood. 1995; 85: 1151-1168.
2. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer. 2003; 3: 639-649.
3. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukaemia. N Engl J Med. 2004; 350: 1535-1548.
4. Cobaleda C, Sanchez-Garcia I. B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin. Bioessays. 2009; 31: 600-609.
5. Hjalgrim LL, Rostgaard K, Schmiegelow K, Soderhall S, Kolmannskog S, Vettenranta K, Kristinsson J, Clausen N, Melbye M, Hjalgrim H, Gustafsson G. Age- and sex-specific incidence of childhood leukaemia by immunophenotype in the Nordic countries. J Natl Cancer Inst. 2003; 95: 1539-1544.
6. Mancini M, Scappaticci D, Cirino G, Nanni M, Derme V, Elia L, Tafuri A, Vignetti M, Vitale A, Cuneo A, Castoldi G, Saglio G, Pane F, et al. A comprehensive genetic classification of adult acute lymphoblastic leukaemia (ALL): analysis of the GIMEMA 0496 protocol. Blood. 2005; 105: 3434-3441.
7. Beerman I, Bhattacharya D, Zandi S, Sigvardsson M, Weissman IL, Bryder D, Rossi DJ. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci U S A. 107: 5465-5470.
8. Gazit R, Weissman IL, Rossi DJ. Hematopoietic stem cells and the aging hematopoietic system. Semin Hematol. 2008; 45: 218-224.
9. Morrison SJ, Wandycz AM, Akashi K, Globerson A, Weissman IL. The aging of hematopoietic stem cells. Nat Med. 1996; 2: 1011-1016.
10. Rossi DJ, Bryder D, Weissman IL. Hematopoietic stem cell aging: mechanism and consequence. Exp Gerontol. 2007; 42: 385-400.
11. Rossi DJ, Bryder D, Zahn JM, Ahlenius H, Sonu R, Wagers AJ, Weissman IL. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A. 2005; 102: 9194-9199.
12. Rossi DJ, Seita J, Czechowicz A, Bhattacharya D, Bryder D, Weissman IL. Hematopoietic stem cell quiescence attenuates DNA damage response and permits DNA damage accumulation during aging. Cell Cycle. 2007; 6: 2371-2376.
13. Allman D, Miller JP. The aging of early B-cell precursors. Immunol Rev. 2005; 205: 18-29.
14. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol. 2004; 5: 133-139.
15. Miller JP, Allman D. The decline in B lymphopoiesis in aged mice reflects loss of very early B-lineage precursors. J Immunol. 2003; 171: 2326-2330.
16. Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N, Rowan R, Amaral S, Curley D, Williams IR, Akashi K, Gilliland DG. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004; 6: 587-596.

17. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, Flores T, Garcia-Sanz R, Gonzalez M, Sanchez-Garcia I. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukaemia. Blood. 2000; 95: 1007-1013.

18. Cox CV, Evely RS, Oahill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukaemia progenitor cells. Blood. 2004; 104: 2919-2925.

19. Cobaleda C, Sanchez-Garcia I. In vivo inhibition by a sitespecific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment. Blood. 2000; 95: 731-737.

20. Perez-Caro M, Gutierrez-Cianca N, Gonzalez-Herrero I, Lopez-Hernandez I, Flores T, Orfao A, Sanchez-Martin M, Gutierrez-Adan A, Pintado B, Sanchez-Garcia I. Sustained leukemic phenotype after inactivation of BCR-ABLp190 in mice. Oncogene. 2007; 26: 1702-1713.

21. Henry CJ, Marusyk A, Zaberezhnyy V, Adene B, Degregori J. Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis. Proc Natl Acad Sci U S A. 2010; doi/10.1073/pnas.1005486107.

22. Schebesta A, McManus S, Salvagiotto G, Delogu A, Busslinger GA, Busslinger M. Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function. Immunity. 2007; 27: 49-63.